29 news items
JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target
CYTK
31 May 24
JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:CYTK) with a Market Outperform and maintains $78 price target.
Truist Securities Maintains Buy on Cytokinetics, Lowers Price Target to $70
CYTK
29 May 24
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $86 to $70.
JMP Securities Maintains Market Outperform on Cytokinetics, Lowers Price Target to $78
CYTK
28 May 24
JMP Securities analyst Jason Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and lowers the price target from $106 to $78.
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
CYTK
RPRX
23 May 24
interpret that M&A is now off the table following several prior rumors and speculation.”
The analyst has updated the price target
HC Wainwright & Co. Maintains Buy on Cytokinetics, Lowers Price Target to $90
CYTK
23 May 24
HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $94 to $90.
6la6qy36cyyp28 lf9s61fwjy6hn6lww3
CYTK
23 May 24
B of A Securities analyst Jason Zemansky maintains Cytokinetics (NASDAQ:CYTK) with a Neutral and lowers the price target from $70 to $60.
cmvm6trpzndxb7r6kkfyjphyhl3m5zpqxrqxan ap
CYTK
23 May 24
Barclays analyst Carter Gould maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $100 to $95.
ltoyza1idi0wch2n92tk5z 2b0xkzulvobve8vrnul97
CYTK
23 May 24
Raymond James analyst Sean McCutcheon maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $92 to $70.
4mjtt7ys7p7sd3ctk47ltggzr ce1xmm7sxt9ubsvsnd9ch8xq2selzw
ADI
AGS
CB
23 May 24
the price target for NVIDIA Corporation (NASDAQ:NVDA) from $1,100
6vfiyz5 lnazcukpk6nd0zylwqcsix72zjum62xt29sxybuq7l48
CYTK
23 May 24
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $108 to $72.
6z4ez
CYTK
RPRX
22 May 24
activator, the first of a novel class of myotropes1 designed to directly target the contractile mechanisms of the heart, binding
bkrs2mksi n2fntyi
CYTK
RPRX
22 May 24
designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin heads to interact with actin during
175j079d690y5h58by0y0be3g6eihqztws3gutuih4qkfltzrnt0e14
CYTK
15 May 24
and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors
2o1v7ra334gyym829qan3yiukrs5xplvfeolo0k1m8
CYTK
14 May 24
JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:CYTK) with a Market Outperform and maintains $106 price target.
4ok wd56imfcuzhq
CYTK
14 May 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $94 price target.
961kdupgixrpgu4gc6pci4qkrsoqomtdh5j7g
CYTK
14 May 24
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $108 price target.
qix6 8xa5vcbuz6nni
CYTK
13 May 24
target dose of aficamten resulted in dose-related increases in plasma drug concentrations with the majority of patients achieving one of the two
y2h06xmup1ah42qrmiq30fyrcig9tzz1g0d1izggywtwqw5zl
CYTK
9 May 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $94 price target.
mcasdtzo6tzonhwyneqlhbfznma6qry0g saon8iksjgwzxi4bq
CYTK
9 May 24
JMP Securities analyst Jason Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and lowers the price target from $110 to $106.
4y6apemu5ejxrvsalyjcgb9ylb7skdtq1c w7115porfbxeqz
CYTK
9 May 24
Oppenheimer analyst Justin Kim maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $107 to $106.